Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis
Semaglutide produced rapid, sustained, and primarily bolus-driven insulin dose reductions, with early effects being largely independent of weight loss in adults with T1D and obesity.
Authors
- Courtney A. Ackeifi (ORCID: https://orcid.org/0000-0002-7110-5841)
- Kagan Karakus
- Andrew A. Ahmann
- Christine R. Langel
- Halis K. Akturk
- Jonathan Rosen (ORCID: https://orcid.org/0009-0001-4409-7110)
- Laura Pyle
- Davida Kruger
- Viral N. Shah
- Anuj Bharvaga
- Janet K. Snell-Bergeon
Institutions
- Henry Ford Health System (US)
- Borough of Manhattan Community College (US)
- Oregon Health & Science University (US)
- University of Washington (US)
- Iowa Diabetes and Endocrinology Research Center (US)
- Indiana University School of Medicine
- University of Colorado Anschutz Medical Campus (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-12-22
- DOI
- https://doi.org/10.2337/dc25-2249
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- American Diabetes Association
- Amgen
- Eli Lilly and Company
- Sanofi
- Alexion Pharmaceuticals
- George Washington University
- Insulet Corporation
- MannKind Corporation
- Dexcom
- Kowa Company
- Tandem Diabetes Care
- Novo Nordisk
- National Institutes of Health
- School of Medicine, Indiana University
- Abbott Diabetes Care
- Anschutz Medical Campus, University of Colorado